Log in

Tetraphase Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TTPH)

+0.25 (+5.41 %)
(As of 10/23/2019 01:24 AM ET)
Today's Range
Now: $4.87
50-Day Range
MA: $2.48
52-Week Range
Now: $4.87
Volume32,680 shs
Average Volume41,469 shs
Market Capitalization$13.23 million
P/E RatioN/A
Dividend YieldN/A
Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:TTPH



Sales & Book Value

Annual Sales$18.90 million
Book Value$29.72 per share


Net Income$-72,160,000.00
Net Margins-1,072.60%


Market Cap$13.23 million
Next Earnings Date11/14/2019 (Estimated)

Receive TTPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TTPH and its competitors with MarketBeat's FREE daily newsletter.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Frequently Asked Questions

What is Tetraphase Pharmaceuticals' stock symbol?

Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."

When did Tetraphase Pharmaceuticals' stock split? How did Tetraphase Pharmaceuticals' stock split work?

Shares of Tetraphase Pharmaceuticals reverse split on the morning of Friday, September 27th 2019. The 1-20 reverse split was announced on Thursday, September 26th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 26th 2019. An investor that had 100 shares of Tetraphase Pharmaceuticals stock prior to the reverse split would have 5 shares after the split.

How were Tetraphase Pharmaceuticals' earnings last quarter?

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) issued its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($8.40) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($7.60) by $0.80. The biopharmaceutical company had revenue of $1.07 million for the quarter, compared to analysts' expectations of $2.13 million. Tetraphase Pharmaceuticals had a negative return on equity of 118.65% and a negative net margin of 1,072.60%. View Tetraphase Pharmaceuticals' Earnings History.

When is Tetraphase Pharmaceuticals' next earnings date?

Tetraphase Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Tetraphase Pharmaceuticals.

What price target have analysts set for TTPH?

7 brokers have issued 1-year price objectives for Tetraphase Pharmaceuticals' shares. Their forecasts range from $28.00 to $80.00. On average, they anticipate Tetraphase Pharmaceuticals' stock price to reach $58.00 in the next twelve months. This suggests a possible upside of 1,091.0% from the stock's current price. View Analyst Price Targets for Tetraphase Pharmaceuticals.

What is the consensus analysts' recommendation for Tetraphase Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tetraphase Pharmaceuticals in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tetraphase Pharmaceuticals.

What are Wall Street analysts saying about Tetraphase Pharmaceuticals stock?

Here are some recent quotes from research analysts about Tetraphase Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "We are reiterating our Hold rating on PCRX shares after the company reported 2Q19 Exparel sales which were in-line with consensus. Given 3Q tends to be a low Q/Q growth quarter due to seasonality, we think this sets up the need for a big 4Q19 Exparel sales number for the company to beat guidance and for shares to meaningfully outperform. Additionally, we would expect shares to be volatile around updates from competitors HRTX (Buy, $17.87) and DRRX (Adam Walsh, Hold, $1.43) which we expect in the coming months – with positive updates from one or both weighing on shares. Overall, we continue to remain on the sidelines as we think shares seem fairly valued at these levels and the potential for incoming competition in the next ~6-12 months poses a headwind, in our view. Key Points Exparel sales met 2Q19 expectations and FY19 Exparel sales guidance was reiterated." (8/11/2019)
  • 2. According to Zacks Investment Research, "Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. " (5/16/2019)
  • 3. Needham & Company LLC analysts commented, "Tetraphase reported $0.3M in U.S. Xerava sales, below our $2.5M and consensus $2M ests. We remain concerned that the commercial opportunity for the drug may be modest. Tetraphase continues to evaluate next-generation IV Gram- negative antibiotic 1 bronchopulmonary disposition trial. We expect an update on development strategy later this yr. Acinetobacter is a potential target pathogen. Preclinical studies of tetracycline oncology derivative TP-2846 are ongoing. Mgmt plans to provide more clarity around strategy and development path once these studies are completed. Maintain HOLD. We believe the company is likely to continue to face challenges w/ Xerava launch. Nevertheless, we have a favorable view toward decision to leverage synthetic tetracycline platform to expand into oncology." (5/12/2019)

Has Tetraphase Pharmaceuticals been receiving favorable news coverage?

News coverage about TTPH stock has been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tetraphase Pharmaceuticals earned a daily sentiment score of -1.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Tetraphase Pharmaceuticals.

Are investors shorting Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals saw a decrease in short interest in September. As of September 30th, there was short interest totalling 54,800 shares, a decrease of 94.6% from the August 30th total of 1,010,000 shares. Based on an average trading volume of 601,500 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the shares of the company are short sold. View Tetraphase Pharmaceuticals' Current Options Chain.

Who are some of Tetraphase Pharmaceuticals' key competitors?

What other stocks do shareholders of Tetraphase Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tetraphase Pharmaceuticals investors own include Aurinia Pharmaceuticals (AUPH), Alcoa (AA), General Electric (GE), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Bank of America (BAC), Verastem (VSTM), Progenics Pharmaceuticals (PGNX), Rite Aid (RAD) and Opko Health (OPK).

Who are Tetraphase Pharmaceuticals' key executives?

Tetraphase Pharmaceuticals' management team includes the folowing people:
  • Mr. Guy MacDonald B.Sc., B.Sc, CEO, Pres & Director (Age 60)
  • Mr. Christopher Watt, Principal Financial & Accounting Officer (Age 54)
  • Dr. Jacques Dumas, Chief Scientific Officer (Age 53)
  • Ms. Maria D. Stahl, Sr. VP & Gen. Counsel (Age 48)
  • Mr. Larry G. Edwards, Chief Operating Officer (Age 47)

How do I buy shares of Tetraphase Pharmaceuticals?

Shares of TTPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Tetraphase Pharmaceuticals' stock price today?

One share of TTPH stock can currently be purchased for approximately $4.87.

How big of a company is Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals has a market capitalization of $13.23 million and generates $18.90 million in revenue each year. The biopharmaceutical company earns $-72,160,000.00 in net income (profit) each year or ($27.40) on an earnings per share basis. Tetraphase Pharmaceuticals employs 119 workers across the globe.View Additional Information About Tetraphase Pharmaceuticals.

What is Tetraphase Pharmaceuticals' official website?

The official website for Tetraphase Pharmaceuticals is http://www.tphase.com/.

How can I contact Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals' mailing address is 480 ARSENAL STREET SUITE 110, WATERTOWN MA, 02472. The biopharmaceutical company can be reached via phone at 617-715-3600 or via email at [email protected]

MarketBeat Community Rating for Tetraphase Pharmaceuticals (NASDAQ TTPH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  347 (Vote Outperform)
Underperform Votes:  327 (Vote Underperform)
Total Votes:  674
MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote "Outperform" if you believe TTPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Featured Article: What is operating income?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel